TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01932086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread
Description: All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
Study: NCT02591927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-Insulin-Potassium
Description: Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
Study: NCT02378402

Intervention type: OTHER
Intervention: Proton (1H-) magnetic resonance (MR) spectroscopy
Description: PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.

Intervention type: OTHER
Intervention: Proton (1H-) magnetic resonance (MR) spectroscopy
Description: PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.

Intervention type: OTHER
Intervention: Proton (1H-) magnetic resonance (MR) spectroscopy
Description: PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
Study: NCT02444234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid PO
Description: Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
Study: NCT02591927

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose 5%
Description: Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
Study: NCT04366401

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dietary Advice
Description: The education content in the control group will be centered on the acquisition of knowledge about:~* - Underlying mental pathology, lifestyles and associated comorbidities~* - Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* - Water requirements.~* - Foodstuffs.~* - Culinary techniques: conservation of properties of the diet.~* - Feeding in particular situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prebiotic/Probiotic Dietary Modulation
Description: The education content in the intervention group will be based on general principles of conventional dietary advice in an intensified manner, centered on the acquisition of specific knowledge about:~* - Underlying mental pathology, lifestyles and associated comorbidities~* - Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* - Water requirements.~* - Foodstuffs.~* - Description and justification of prescribed prebiotic and probiotic diet.~* - Culinary techniques: conservation of properties of the prebiotic and probiotic diet.~* - Optimal distribution and interchange of foods with high prebiotic and probiotic content.~* - Feeding in particular situations.
Study: NCT02466880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: A diabetes self-management and education program delivered via telemedicine
Study: NCT00870103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Description: 1 drop every 6 hours into the study eye
Study: NCT03654573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorFlow Controlled Flow Infusion System - CoFI™
Description: The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
Study: NCT02585570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
Study: NCT04352153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uralyt-U
Description: Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
Study: NCT03613272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subxiphoid approach extended thymectomy by VATS
Description: Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal approach extended thymectomy by VATS
Description: Extended thymectomy performed through the traditional intercostal VATS approach
Study: NCT02444234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid IV
Description: Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
Study: NCT01873547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell therapy
Description: Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: Patients only receive rehabilitation of limb function.
Study: NCT06393686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: The yoga intervention will be implemented every two weeks, with each session lasting 45 minutes and implemented for 10 weeks. Sessions will always be led by the same certified yoga instructor. Each session will include a variety of different yoga poses, as well as breathing techniques and deep relaxation methods.
Study: NCT02882152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral nerve blockade
Description: femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Intrathecal morphine injection
Study: NCT02133170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard treatment
Description: Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
Study: NCT02248688

Intervention type: DEVICE
Group type: OTHER
Intervention: BeadBlock 300 - 500 Micron
Description: Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Left Gastric Artery Embolization
Study: NCT03860935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acoramidis
Description: TTR stabilizer administered orally twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Non-active control administered orally twice daily (BID)
Study: NCT01463007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: Accuboost APBI 34.0 Gy in 10 fractions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Follow up
Description: This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
Study: NCT03190044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PACR
Description: Daily assumption of PACR for a 3-month period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily assumption of placebo
Study: NCT00634738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Compression (thumb Pressure)
Description: Pressure, one thumb on the other, applied on the trigger points
Study: NCT04321785

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule (mannitol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: caffeine capsule (80 mg of caffeine plus mannitol)
Study: NCT00477958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
Study: NCT02706223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Led
Description: Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse led
Description: Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
Study: NCT02186301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib Mono-Therapy
Description: Rociletinib will be administered twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib Mono-Therapy
Description: Erlotinib will be administered once a day
Study: NCT03879343

Intervention type: OTHER
Intervention: Known diagnosis of attention deficit / hyperactivity disorder
Description: Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
Study: NCT02528721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Mode BreathID Hp System
Description: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Mode BreathID Hp System
Description: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
Study: NCT04396184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study: NCT02883699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard endurance training
Description: Continuous vigorous training 2 x per week on a cycle ergometer
Study: NCT00482222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT01343823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide 60 mg
Description: Administered as two 3 mL SC injections, each containing 30 mg ecallantide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide 30 mg
Description: Administered as one 3 mL SC injection containing 30 mg ecallantide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide 10 mg
Description: Administered as one 3 mL SC injection containing 10 mg ecallantide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered as two SC 3 mL injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo match for 30 mg ecallantide arm
Description: One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo match for 10 mg ecallantide arm
Description: One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
Study: NCT02883699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polarized endurance training
Description: Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard resistance training
Description: Machine based hypertrophy training 2 x per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily undulating periodization resistance training
Description: Machine based daily undulating periodization resistance training 1 x per week
Study: NCT01685645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlgiScan
Description: The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
Study: NCT01857557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Patients receiving exercise program in addition to usual headache care
Study: NCT03279627

Intervention type: OTHER
Intervention: Diabetes Management Questionnaire
Description: Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.

Intervention type: OTHER
Intervention: Diabetes Management Questionnaire
Description: Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.

Intervention type: OTHER
Intervention: Diabetes Management Questionnaire
Description: Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
Study: NCT03652623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
Study: NCT03842982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.
Study: NCT01768884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02376959

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spiritist passe
Description: For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique.
Study: NCT03859973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT04120298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: An individualised exercise programme supervised by a trained instructor
Study: NCT03126552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus L3 larvae
Description: 50 Necator americanus L3 larvae
Study: NCT00650481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Extended-release Tablets 5 mg
Description: 4x5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 5 mg
Description: 4x5mg, single dose fasting
Study: NCT04096183

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation of healthy volunteers
Description: Ventilation of healthy volunteers in different clinical situations
Study: NCT00960583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: 24 group exercise sessions during 12 weeks
Study: NCT04947475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
Study: NCT04561505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of prostate
Description: surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monopolar transurethral resection of prostate
Description: surgical management of BPH by monopolar TURP using distilled water for irrigation
Study: NCT00507325

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Blood samples will be collected.

Intervention type: PROCEDURE
Intervention: Tumor Sample
Description: Tumor samples will be collected using a small needle, a punch knife, or a small surgery.